SCHEDULE: Biotech Value Fund Boosts X4 Pharma Stake to 9.9%

Biotechnology Value Fund and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in X4 Pharmaceuticals, Inc., including shares from recently issued pre-funded warrants.

Summary

• Biotechnology Value Fund L.P. (BVF) and its affiliates, including BVF I GP LLC, Biotechnology Value Fund II LP (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in X4 Pharmaceuticals, Inc.
• As of August 20, 2025, the group's aggregate beneficial ownership reached 2,243,659 shares, representing 9.9% of the outstanding common stock.
• This ownership includes 9,917 shares issuable upon the exercise of pre-funded warrants, which are subject to a 9.99% beneficial ownership blocker.
• The total shares outstanding used for calculation were 22,459,050, derived from 11,408,357 shares as of August 4, 2025, plus 11,040,776 shares issued on August 12, 2025, and the 9,917 exercisable warrant shares.
• Individually, BVF beneficially owned 1,168,649 shares (5.2%), BVF2 beneficially owned 906,855 shares (4.0%), and Biotechnology Value Trading Fund OS LP beneficially owned 123,369 shares (0.6%).
• BVF GP Holdings LLC, as the sole member of BVF GP and BVF2 GP, was deemed to beneficially own 2,075,504 shares (9.2%).

Sentiment

Score: 8

Explanation: The filing indicates a significant and committed investment by a specialized biotechnology fund, which is generally a strong positive signal for a company, especially in the capital-intensive biotech sector. The acquisition of a substantial stake, including through warrants, suggests confidence in the company's long-term value.

Positives

• The disclosure of a significant 9.9% beneficial ownership by a specialized biotechnology investment group, Biotechnology Value Fund, signals strong institutional confidence in X4 Pharmaceuticals, Inc.
• The holding of pre-funded warrants and their partial exercise indicates a long-term commitment and belief in the company's future prospects.
• The investment group explicitly states that the securities were not acquired for the purpose of changing or influencing control, suggesting a focus on investment returns rather than activism.

Risks

• The pre-funded warrants held by the reporting persons are subject to a 9.99% beneficial ownership blocker, limiting the immediate exercise of a substantial portion of the warrants (1,288,288 total underlying shares, but only 9,917 currently exercisable).

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant increase in institutional ownership by a specialized biotechnology investment fund in X4 Pharmaceuticals. Such investments are common in the biotech sector, where companies often rely on capital raises and strategic investments to fund research, development, and commercialization efforts. A substantial stake by a reputable fund can be viewed as a positive signal of confidence in the company's pipeline and strategic direction within the competitive biotechnology landscape.

Related Party Transactions

• The various Biotechnology Value Fund entities (BVF, BVF2, Trading Fund OS, BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc., and Mark N. Lampert) are acting as a group and are related parties in their collective beneficial ownership of X4 Pharmaceuticals, Inc. shares.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a specialized fund can enhance investor confidence and potentially lead to increased trading liquidity and share price stability.
• Company Management: The significant stake by a major investor may influence strategic decisions, although the filing states the investment is not for control purposes.

Key Dates

Recommendation

The substantial beneficial ownership stake acquired by Biotechnology Value Fund, a specialized and experienced investor in the biotech sector, signals a strong vote of confidence in X4 Pharmaceuticals. This institutional backing, coupled with the exercise of pre-funded warrants, suggests a belief in the company's long-term value proposition and future growth potential. Such a significant investment from a reputable fund can be a positive catalyst for the stock.

Keywords

X4 Pharmaceuticals, Biotechnology Value Fund, SEC filing, Schedule 13G, beneficial ownership, biotech, common stock, institutional investment, warrants, equity stake